Currently, a model consisting of PSA, %free PSA, DRE, and WFDC2 has been reported to differentiate clinically significant prostate cancer from non-cancer, potentially reducing unnecessary biopsies (Shore et al., 2023). The gene discussed is KLK3; the disease is cancer.